Company news
MaxCyte, Inc. news in 2022
MaxCyte, Inc.'s news releases, calls and decks from 2022, newest first.
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
December 3, 2022
MaxCyte Reports Third Quarter 2022 Financial Results
November 8, 2022
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
October 11, 2022
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
September 27, 2022
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
September 20, 2022
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
August 9, 2022
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
July 14, 2022
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
July 11, 2022
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2022
MaxCyte Reports First Quarter Financial Results
May 8, 2022
MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
April 19, 2022
MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue
April 11, 2022
MaxCyte Reports Fourth Quarter and Full Year Financial Results
March 21, 2022
MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer
March 8, 2022
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
January 31, 2022
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results
January 22, 2022